Allogeneic bone marrow transplantation in Korea: 1983-92

Area of Science:

• Hematology
• Oncology
• Transplantation

Background:

• Allogeneic bone marrow transplantation (BMT) is a critical treatment for various hematopoietic stem cell disorders.
• The study retrospectively analyzes BMT outcomes between 1983 and 1992.

Purpose of the Study:

• To evaluate the efficacy and survival rates of allogeneic BMT in patients with diverse hematologic malignancies and disorders.
• To assess the impact of disease risk and preparative regimens on transplant outcomes, particularly in acute myelogenous leukemia (AML).

Main Methods:

• Retrospective analysis of 178 allogeneic BMT procedures performed between March 1983 and December 1992.
• Categorization of patients by diagnosis, including acute myelogenous leukemia (AML), acute lymphoblastic leukemia (ALL), chronic myelogenous leukemia (CML), and severe aplastic anemia (SAA).
• Comparison of survival outcomes based on disease status (e.g., CR1 vs. CR2 for AML) and transplant phases (e.g., CP vs. AP/BC for CML).

Main Results:

• Disease-free survival (DFS) was observed in 25 of 48 AML patients and 24 of 40 CML patients.
• Unmaintained remission was achieved by 15 of 27 ALL patients.
• Forty-four of 55 SAA patients were alive and well, with an estimated 5-year survival of 80% +/- 4%.
• High-risk AML patients (>= CR2) showed significantly lower survival (24%) compared to standard-risk (<= CR1) AML patients (68%), suggesting inadequate preparative regimens.
• Promising overall survival rates were noted for ALL (56%) and CML (60%), with better outcomes in earlier disease stages.

Conclusions:

• Allogeneic BMT offers encouraging survival benefits for ALL, CML, and SAA patients.
• The preparative regimen for high-risk AML requires optimization to improve outcomes in advanced disease.
• Further research with larger cohorts and longer follow-up is warranted to refine BMT strategies for hematologic stem cell disorders.